Loading stock data…
Novo Nordisk A/S (NVO)
$48.34+0.27 (+0.56%)
After Hours$48.17-0.17 (-0.36%)· Last close Jun 29
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novo Nordisk A/S in the Healthcare sector is trading at $48.34 with a market capitalization of $192.7B. Wall Street consensus targets $47.53 (12 analysts), implying a -1.7% move over the next 12 months. The stock is currently 33% below its 52-week high of $71.80, remaining 3.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $96.82B↑ | $79.14B↑ | $74.98B↓ | $76.86B↓ | $78.09B |
| Gross Profit | $83.22B↑ | $64.00B↑ | $57.07B↓ | $64.01B↓ | $65.20B |
| Operating Income | $59.62B↑ | $31.74B↑ | $23.68B↓ | $33.45B↓ | $38.79B |
| Net Income | $48.56B↑ | $26.89B↑ | $20.01B↓ | $26.50B↓ | $29.03B |
Peer Comparison
JNJUNHPFE
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$192.71B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.65%
ROE
Elite ROE. Management converts capital into profit efficiently.
60.06%
Volume
Today's trading volume
7.67M
Recent News
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
3 late-stage MASH drugs that could rival Rezdiffra
The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.
Is Novo Nordisk (NVO) One of the Best Low Volatility Stocks to Buy Under $50?
Novo Nordisk A/S (NYSE:NVO) is one of the best low volatility stocks to buy under $50. Novo Nordisk A/S (NYSE:NVO) announced on June 11 that the Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The […]